Sinovac Biotech Revenue 2006-2020 | SVA

Sinovac Biotech revenue from 2006 to 2020. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Sinovac Biotech Annual Revenue
(Millions of US $)
2020 $511
2019 $246
2018 $230
2017 $174
2016 $72
2015 $67
2014 $63
2013 $72
2012 $49
2011 $57
2010 $33
2009 $84
2008 $46
2007 $34
2006 $15
2005 $9
Sinovac Biotech Quarterly Revenue
(Millions of US $)
2020-12-31 $327
2020-09-30 $115
2020-06-30 $52
2020-03-31 $15
2019-12-31 $81
2019-09-30 $64
2019-06-30 $64
2019-03-31 $37
2018-12-31 $53
2018-09-30
2018-06-30 $75
2018-03-31 $47
2016-12-31 $31
2016-09-30 $29
2016-06-30 $1
2016-03-31 $11
2015-12-31 $23
2015-09-30 $17
2015-06-30 $18
2015-03-31 $9
2014-12-31 $20
2014-09-30 $17
2014-06-30 $12
2014-03-31 $14
2013-12-31 $23
2013-09-30 $22
2013-06-30 $17
2013-03-31 $10
2012-12-31 $19
2012-09-30 $14
2012-06-30 $9
2012-03-31 $6
2011-12-31 $21
2011-09-30 $15
2011-06-30 $16
2011-03-31 $5
2010-12-31 $9
2010-09-30 $10
2010-06-30 $10
2010-03-31 $4
2009-12-31 $36
2009-09-30 $21
2009-06-30 $20
2009-03-31 $7
2008-12-31 $12
2008-09-30 $9
2008-06-30 $17
2008-03-31 $9
2007-12-31 $9
2007-09-30 $11
2006-12-31
2005-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.642B $0.511B
Sonovac Biotech Ltd. specializes in the research, development, commercialization, and sales of human vaccines for infectious illnesses such as hepatitis A and hepatitis B, influenza, `SARS`, and avian flu. Sinovac is one of the leading emerging biotechnology companies in China.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00